Oscient Pharmaceuticals to Present at Fifth Annual JMP Securities Research Conference.WALTHAM, Mass. -- - Webcast of presentation available Thursday, March 9, 2006 at 8:35 AM PT (11:35 AM ET) - Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) will participate in the Fifth Annual JMP Securities Research Conference on March 9, 2006 in San Francisco, California “San Francisco” redirects here. For other uses, see San Francisco (disambiguation). The City and County of San Francisco (EN IPA: [sænfrənˈsɪskoʊ] . The Company's President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Steven Rauscher, will provide an overview of the Company including details on the recent sublicense of FACTIVE Fac´tive a. 1. Making; having power to make. (R) (gemifloxacin mesylate) tablets in Mexico to Pfizer, S.A. de C.V and the acquisition of expanded worldwide rights for the Company's lead clinical candidate, Ramoplanin. The presentation will begin at 8:35 AM PT (11:35 AM ET) on Thursday and will be webcast through the Company's website at www.oscient.com. An archive of the webcast will also be available for 90 days. About Oscient Pharmaceuticals Oscient Pharmaceuticals Corporation is a biopharmaceutical company committed to the clinical development and commercialization of novel therapeutics to address unmet medical needs. The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. for the five-day treatment of acute bacterial exacerbations of chronic bronchitis and the seven-day treatment of community-acquired pneumonia of mild to moderate severity. In addition to the oral tablet form, Oscient is developing an investigational FACTIVE intravenous formulation for use in hospitalized patients. The Company is also promoting Auxilium Pharmaceuticals' TESTIM(R) 1% testosterone gel to primary care physicians in the U.S. Oscient has a novel antibiotic candidate, Ramoplanin, in advanced clinical development for the treatment of Clostridium clostridium Any of the rod-shaped, usually gram-positive bacteria (see gram stain) that make up the genus Clostridium. They are found in soil, water, and the intestinal tracts of humans and other animals. Some species grow only in the complete absence of oxygen. difficile-associated disease (CDAD CDAD Clostridium Difficile-Associated Diarrhea CDAD Component Data Administrator ). |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion